Lacutamab has progressed to the Phase II TELLOMAK trial (NCT03902184), which is assessing the antibody’s efficacy and safety in patients with advanced cutaneous T-cell lymphoma (CTLC). Lacutamab is under study in patients with mycosis fungoides and two other CTLC subtypes . . .
The post Innate Immunity: French Biotech Builds Antibody Pipeline against Cancer appeared first on GEN – Genetic Engineering and Biotechnology News.
